Zhang, Zhuming

Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development

Ding, Q., Zhang, Z., Liu, J.-J., Jiang, N., Zhang, J., Ross, T. M., Chu, X.-J., Bartkovitz, D., Podlaski, F., Janson, C., et al. (2013) · Journal of Medicinal Chemistry

Cancer-related Molecular PathwaysPI3K/AKT/mTOR signaling in cancer

Cited by 595

The impact of physical activity on the prevention of type 2 diabetes: Evidence and lessons learned from the Diabetes Prevention Program, a long-standing clinical trial incorporating subjective and objective activity measures

Kriska, A. M., Rockette-Wagner, B., Edelstein, S. L., Bray, G. A., Delahanty, L. M., Hoskin, M. A., Horton, E. S., Venditti, E. M., Knowler, W. C., DPP Research Group, et al. (2021) · Diabetes Care

Physical Activity and HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 70

Assessing IRAK4 Functions in ABC DLBCL by IRAK4 Kinase Inhibition and Protein Degradation

Zhang, J., Fu, L., Shen, B., Liu, Y., Wang, W., Cai, X., Kong, L., Yan, Y., Meng, R., Zhang, Z., et al. (2020) · Cell Chemical Biology

Protein Degradation and InhibitorsLymphoma Diagnosis and Treatment

Cited by 63

Discovery of potent and selective spiroindolinone MDM2 inhibitor, RO8994, for cancer therapy

Zhang, Z., Ding, Q., Liu, J.-J., Zhang, J., Jiang, N., Chu, X.-J., Bartkovitz, D., Luk, K.-C., Janson, C., Tovar, C., et al. (2014) · Bioorganic & Medicinal Chemistry

Cancer-related Molecular PathwaysHeterocyclic Compound Synthesis and Bioactivity

Cited by 60

The Diabetes Prevention Program and Its Outcomes Study: NIDDK’s Journey Into the Prevention of Type 2 Diabetes and Its Public Health Impact

Crandall, J. P., Dabelea, D., Knowler, W. C., Nathan, D. M., Temprosa, M., DPP Research Group, Bray, G. A., Gadde, K. M., Culbert, I. W., Arceneaux, J., et al. (2025) · Diabetes Care

Diabetes, Cardiovascular Risks, and LipoproteinsDiabetes Treatment and Management

Cited by 29